Novartis has achieved significant regulatory successes on two fronts, with its oral therapy Rhapsido (remibrutinib) receiving marketing authorisation from the…
Read More
New Qulipta Study Data Bolsters Case Against Restrictive European Reimbursement Policies
New clinical trial results presented by AbbVie are poised to significantly influence the landscape of migraine prevention in Europe, providing…
Read More
Jeito Capital’s Second Fund Closes Above Target, Bolstering European Biopharma Investment to Over €1.6 Billion
Global independent private equity fund Jeito Capital has achieved a significant milestone in European biopharma investment with the successful closure…
Read More
US Import Tariffs Fail to Deter Biopharma Giants as European Contract Manufacturing Surges for FDA-Approved Drugs
The biopharmaceutical industry is demonstrating a significant and counterintuitive trend in 2025, with companies increasingly channeling investments into European-based contract…
Read More
European Commission Approves Keytruda Combination Therapy for PD-L1-Positive Platinum-Resistant Ovarian Cancer
The European Commission (EC) has granted approval for Keytruda (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, as a…
Read More
Darzalex Secures Landmark European Approval for Self-Administration in Multiple Myeloma, Ushering in a New Era of Home-Based Cancer Care
Johnson & Johnson’s (J&J) groundbreaking cancer immunotherapy, Darzalex (daratumumab), has achieved a pivotal milestone in its European market penetration with…
Read More
The Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
On May 12, 2025, a significant executive order signed by then-US President Donald Trump mandated the US Department of Health…
Read MoreYOU MAY HAVE MISSED
